Our findings identify FKBP51 as a key mediator of ischemic synaptic dysfunction and suggest that cDCS may exert its therapeutic effects through FKBP51-dependent regulation of plasticity, thereby offering new targets for the treatment of ischemic brain injury. Here, FKBP5 is linked to brain injury.